IdexIEX
- Legal name
- Idex Corp.
- Sector
- Other
- Industry
- Pumps & Pumping Equipment
- Exchange
- NYSE
Stock Price $IEX
Latest filings
You are here#103 of 116 in Industrials by market cap
Area = market cap · hover a tile to read it
IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 28, 2016
- 8-K · Feb 3, 2016
- 8-K · Feb 10, 2016
- 10-K · Feb 19, 2016
- 8-K · Feb 19, 2016
- 8-K · Mar 18, 2016
- 8-K · Apr 12, 2016
- 8-K · Apr 19, 2016
- 10-Q · Apr 25, 2016
- 8-K · Apr 25, 2016
- 8-K · Jun 15, 2016
- 8-K · Jul 19, 2016
- 8-K · Jul 25, 2016
- 8-K · Jul 28, 2016
- 10-Q · Aug 1, 2016
- 8-K · Sep 2, 2016
- 8-K · Oct 18, 2016
- 8-K · Oct 21, 2016
- 10-Q · Oct 25, 2016
- 8-K · Nov 8, 2016
- 8-K · Jan 4, 2017
- 8-K · Jan 31, 2017
- 8-K · Feb 2, 2017
- 10-K · Feb 23, 2017
- 8-K · Feb 23, 2017
- 8-K/A · Mar 8, 2017
- 8-K · Apr 20, 2017
- 8-K · Apr 25, 2017
- 10-Q · Apr 26, 2017
- 8-K · Apr 27, 2017
- 8-K · Jul 26, 2017
- 10-Q · Jul 26, 2017
- 8-K · Jul 28, 2017
- 8-K · Oct 17, 2017
- 8-K · Oct 20, 2017
- 10-Q · Oct 23, 2017
- 8-K · Jan 2, 2018
- 8-K · Jan 30, 2018
- 8-K · Feb 2, 2018
- 10-K · Feb 22, 2018
- 8-K · Apr 30, 2018
- 8-K · Apr 30, 2018
- 10-Q · Apr 30, 2018
- 8-K · May 3, 2018
- 8-K · Jul 25, 2018
- 10-Q · Jul 25, 2018
- 8-K · Jul 30, 2018
- 8-K · Oct 24, 2018
- 10-Q · Oct 24, 2018
- 8-K · Jan 30, 2019
- 10-K · Feb 28, 2019
- 10-Q · Apr 26, 2019
- 8-K · Apr 26, 2019
- 8-K · May 14, 2019
- 8-K · Jun 4, 2019
- 8-K · Jun 18, 2019
- 10-Q · Jul 26, 2019
- 8-K · Jul 26, 2019
- 10-Q · Oct 30, 2019
- 8-K · Oct 30, 2019
- 8-K · Jan 30, 2020
- 10-K · Feb 21, 2020
- 8-K · Feb 26, 2020
- 8-K · Apr 24, 2020
- 10-Q · Apr 24, 2020
- 8-K · Apr 29, 2020
- 8-K · May 13, 2020
- 10-Q · Jul 24, 2020
- 8-K · Jul 24, 2020
- 8-K · Oct 28, 2020
- 8-K · Oct 28, 2020
- 10-Q · Oct 28, 2020
- 8-K · Jan 13, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 4, 2021
- 8-K/A · Feb 10, 2021
- 10-K · Feb 25, 2021
- 8-K · Feb 26, 2021
- 8-K · Apr 28, 2021
- 8-K · Apr 28, 2021
- 10-Q · Apr 28, 2021
- 8-K · May 10, 2021
- 8-K · May 14, 2021
- 8-K · May 18, 2021
- 8-K · May 28, 2021
- 8-K · Jun 17, 2021
- 8-K · Jun 21, 2021
- 8-K · Jul 2, 2021
- 8-K · Jul 28, 2021
- 10-Q · Jul 28, 2021
- 8-K · Aug 26, 2021
- 10-Q · Oct 27, 2021
- 8-K · Oct 27, 2021
- 8-K · Feb 2, 2022
- 8-K · Feb 8, 2022
- 10-K · Feb 24, 2022
- 8-K · Feb 28, 2022
- 10-Q · Apr 27, 2022
- 8-K · Apr 27, 2022
- 8-K · May 10, 2022
- 8-K · Jun 16, 2022
- 10-Q · Jul 27, 2022
- 8-K · Jul 27, 2022
- 8-K · Sep 13, 2022
- 8-K · Sep 22, 2022
- 8-K · Oct 26, 2022
- 10-Q · Oct 26, 2022
- 8-K · Nov 2, 2022
- 8-K · Nov 17, 2022
- 8-K · Nov 18, 2022
- 8-K · Dec 16, 2022
- 8-K · Feb 1, 2023
- 10-K · Feb 23, 2023
- 10-Q · Apr 27, 2023
- 8-K · Apr 27, 2023
- 8-K · May 31, 2023
- 8-K · Jun 14, 2023
- 10-Q · Jul 27, 2023
- 8-K · Jul 27, 2023
- 8-K · Aug 30, 2023
- 8-K · Aug 30, 2023
- 8-K · Oct 25, 2023
- 8-K · Oct 26, 2023
- 10-Q · Oct 26, 2023
- 8-K · Feb 7, 2024
- 10-K · Feb 22, 2024
- 10-Q · Apr 24, 2024
- 8-K · Apr 24, 2024
- 8-K · May 8, 2024
- 8-K · Jul 23, 2024
- 8-K · Aug 1, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 8, 2024
- 8-K · Aug 21, 2024
- 8-K · Sep 5, 2024
- 10-Q · Oct 30, 2024
- 8-K · Oct 30, 2024
- 8-K · Feb 4, 2025
- 8-K · Feb 20, 2025
- 10-K · Feb 20, 2025
- 8-K · May 1, 2025
- 10-Q · May 1, 2025
- 8-K · May 12, 2025
- 8-K · May 21, 2025
- 10-Q · Jul 30, 2025
- 8-K · Jul 30, 2025
- 8-K · Sep 18, 2025
- 8-K · Oct 29, 2025
- 10-Q · Oct 29, 2025
- 8-K · Dec 4, 2025
- 8-K · Feb 4, 2026
- 8-K · Feb 9, 2026
- 10-K · Feb 19, 2026
- 8-K · Apr 29, 2026
- 10-Q · Apr 29, 2026
- 8-K · May 8, 2026
- 8-K · Jul 29, 2026
- 10-Q · Jul 29, 2026
- 8-K · Aug 17, 2026
- 8-K · Sep 3, 2026
- 8-K · Oct 28, 2026
- 10-Q · Oct 28, 2026
01—Key figures
Revenue Trend
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025
- $3.46B
1 older move runs past ±20% (largest +21.5%); point at, tap or drag across the bars to read one.
Latest bar from 10-KFY2025Click a bar to open its SEC filingTap a bar to open its SEC filing
View full history →All IEX Financial Metrics59 metrics
Income Statement14
Balance Sheet25
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Receivables
- Inventory
- Prepaid & Other
- PP&E
- Goodwill
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accrued Liabilities
- Short-Term Debt
- Deferred Revenue
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Treasury Stock
- NCI
- Total L&E
Cash Flow15
02—Overview
Idex Financial Overview 2021–2025
Updated Nov 5, 2026IDEX's reported earnings per share fell 18%, from $7.85 in FY2023 to $6.41a in FY2025, even as sales hit a record $3,457.5 million. That gap is the story. The company bought growth with debt, and the cost is showing up below the operating line. The thesis: cash generation is intact and demand is turning, but investors are paying for a recovery that GAAP earnings have yet to show.
Over the longer arc, revenue grew from $2,764.8 million in FY2021 to $3,457.5 millionb in FY2025, a gain of roughly 25%. Reported EPS moved only from $5.88 to $6.41 over the same stretch. The Mott acquisition explains much of the drag. Borrowings rose from $1,333.3 million at the end of FY2023 to $1,971.3 million at the end of FY2024. Net interest expense climbed to $64.4 million in FY2025 from $44.5 million, and the effective tax rate rose to 23.7%.
The cash picture is better. FY2025 free cash flow was $616.8 millionc, or 103% of adjusted net income. IDEX spent $248 million on buybacks and $213 million on dividends. The covenant leverage ratio eased to 1.96x from 2.20x a year earlier. Momentum also improved late in the year: Q4 2025 orders hit a record $979.2 million, up 20%.
The market priced that mix at 27.8x earnings, with shares closing at $177.94d on the final trading day of FY2025.
Recent Developments (Q2 and Q3 2026)
Demand accelerated through mid-2026. Q2 2026 orders hit a record $1,071.6 millione, up 29%, and Q3 2026 sales reached $951.7 million, up 8% organically. Health & Science Technologies sales rose 14% in both quarters on AI-related data center power and semiconductor demand. Adjusted EPS rose 15% to $2.33 in Q3 2026. Management raised full-year adjusted EPS guidance twice, to $8.91–$8.96. Tariff refunds flattered Q2 2026, adding 150 basis points to gross margin. Borrowings fell to $1,759.0 million, and a new $800 million revolver now matures in September 2031. Director L. Paris Watts-Stanfield resigned in August 2026 with no stated disagreement.
The bull case: orders are growing faster than sales, and guidance keeps rising. The bear case: at 37.2x trailing earnings of $6.41 as of October 27, 2026, the stock already prices in the recovery, and Fire & Safety sales fell 1% in Q2 2026.
What to watch: conversion of record orders into Q4 2026 sales; margins once tariff refund benefits fade
03—Filings
Recent SEC Filings
- 8-KIdex 8-K Report, Financial Results (Oct 28, 2026)IDEX Corporation reported record third-quarter 2026 results, with net sales of $951.7 million, up 8% on both a reported and organic basis versus the prior year period. Reported diluted EPS attributable to IDEX was $1.95, up from $1.70, and record adjusted diluted EPS was $2.33, up from $2.03, with both reported and adjusted EPS increasing 15%. Orders were $991.2 million, up 13% on both a reported and organic basis. Gross margin rose to 45.1% from 44.5%, and Adjusted EBITDA margin rose to 27.8% from 27.3%. The Health & Science Technologies segment drove much of the growth, with net sales up 14% and organic sales up 13%, supported by AI-driven demand for data center power and semiconductor markets, as well as space and defense. Cash flow was strong, with operating cash flow of $239.5 million and free cash flow of $214.3 million, compared with $188.7 million a year earlier. The company returned $129 million to shareholders through dividends and share repurchases during the quarter, and it amended and restated its $800 million revolving credit facility to extend maturity to September 2031. Management raised full-year 2026 guidance, now projecting organic sales growth of 6.5% to 6.8%, up from 5% to 6%, and adjusted diluted EPS of $8.91 to $8.96, up from $8.70 to $8.85. The filing furnishes the earnings press release as Exhibit 99.1 under Item 2.02, and that information is not deemed filed for Section 18 purposes.
- 8-KIdex 8-K Report, Material Agreement (Sep 3, 2026)On September 3, 2026, IDEX Corporation entered into an amended and restated credit agreement, dated as of November 1, 2022, with Bank of America, N.A. as administrative agent, swingline lender and letter of credit issuer, together with its subsidiaries as borrowers and a group of lenders and financial institutions. The filing describes the agreement as consisting of an $800 million revolving credit facility with a final maturity date of September 3, 2031. That date extends the November 1, 2027 maturity of the original agreement, and the maturity may be further extended twice, each time by one year, under certain conditions. The facility can be used for working capital and general corporate purposes, including refinancing existing company and subsidiary debt. It includes a sublimit of up to $100 million for letters of credit and up to $50 million for same-day swingline loans. The company may request commitment increases of up to $400 million in aggregate, and may designate certain foreign subsidiaries as borrowers, in which case it must guarantee their obligations. Borrowings bear interest at an alternate base rate or Term SOFR (or applicable alternative currency rates) plus an applicable margin, which is based on the better of the company's senior unsecured long-term debt rating or its leverage ratio. Voluntary prepayments and commitment reductions are permitted without penalty, subject to break funding payments and minimum notice and amount requirements. The agreement contains customary senior unsecured covenants, including a leverage ratio tested quarterly, with an option to increase the ratio for 12 months following certain acquisitions. Negative covenants restrict liens, fundamental changes such as mergers or sales of substantially all assets, certain subsidiary dividends, materially different lines of business, and certain subsidiary debt. The agreement also includes customary events of default, subject to grace periods. The filing notes that the company and the lenders maintain other commercial and investment banking relationships. The full agreement is filed as Exhibit 10.1, with certain schedules omitted under Item 601(a)(5) of Regulation S-K.
- 8-KIdex 8-K Report, Executive Changes (Aug 17, 2026)IDEX Corporation filed a Current Report on Form 8-K dated August 17, 2026, under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). The filing reports that L. Paris Watts-Stanfield resigned from the Board of Directors effective immediately on August 13, 2026. The filing states that Ms. Watts-Stanfield's decision to resign was not the result of any disagreement with the Company on any matters relating to its operations, policies or practices. The Company and the Board thanked her for her service. In connection with the resignation, the size of the Board was reduced from ten to nine directors. This is a governance-related disclosure. The filing does not announce a replacement director, a new officer appointment, or any compensatory arrangement changes.
- 8-KIdex 8-K Report, Financial Results (Jul 29, 2026)IDEX Corporation reported second-quarter 2026 results on July 29, 2026, with record sales of $921 million, up 6% on a reported basis and 5% organically. Net sales were $920.6 million versus $865.4 million a year earlier. Reported diluted EPS was $1.93, up from $1.74, and adjusted diluted EPS was a record $2.32, up 12% from $2.07. Record orders exceeded $1 billion ("$1,071.6 million"), up 29% on a reported basis and 28% organically. Health & Science Technologies drove growth, with net sales up 14% and organic sales up 12%, driven by AI-related data center power and semiconductor demand, space and defense, and positive price. The quarter included a net benefit from IEEPA tariff refunds. The filing says these refunds contributed 150 basis points to gross margin and added $0.08 to both reported and adjusted diluted EPS, partly offset by a $14.7 million reduction in net sales from expected customer rebates tied to the refunds. Operating cash flow was $200.0 million and free cash flow was $177.0 million, up from $146.9 million. The company returned $77 million through share repurchases and paid $54 million in dividends during the quarter. Management raised its full-year 2026 guidance, now projecting organic sales growth of 5% to 6% (previously 3% to 4%) and adjusted diluted EPS of $8.70 to $8.85 (previously $8.35 to $8.55). Third-quarter guidance calls for organic sales growth of 5% to 7% and adjusted diluted EPS of $2.20 to $2.25. The filing attributes the raised outlook to strong year-to-date performance and improved second-half visibility.
- 8-KIdex 8-K Report, Shareholder Vote Results (May 8, 2026)IDEX Corporation held its Annual Meeting of Stockholders on May 6, 2026, and reported the results of three shareholder votes in this Form 8-K. Stockholders elected four Class I directors, Mark A. Beck, Carl R. Christenson, Katrina L. Helmkamp and Alejandro Quiroz Centeno, to three-year terms expiring at the 2029 annual meeting. Beck received 62,032,187 votes for and 4,324,559 against, while Quiroz Centeno received 65,577,289 for and 778,817 against. Stockholders also approved, on an advisory basis, the compensation of the company's named executive officers, with 58,071,019 affirmative votes, 7,464,627 negative votes, 829,154 abstentions and 1,305,842 broker non-votes. The proposal to ratify Deloitte & Touche LLP as the independent registered public accounting firm for 2026 received 58,038,340 affirmative votes, 9,627,072 negative votes and 5,230 abstentions. Each proposal received the affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote on the matter. The filing reports governance outcomes only. It contains no financial results, guidance or other operating information, and its single exhibit is the Inline XBRL cover page.
04—See also
Related Companies
Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.